SCHEMBL2857233

SCHEMBL2857233

Cc1ccc(N)cc1C(=O)c1ccc(Br)cc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 5/20 0.52
MAPK12 P53778 5/20 0.52
MAPK11 Q15759 5/20 0.52
MAPK14 Q16539 5/20 0.52
CYP3A4 P08684 1/20 0.43
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.39
FLT1 P17948 2/20 0.38
FLT4 P35916 2/20 0.38
KDR P35968 2/20 0.38
MAPK1 P28482 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.38
CASP1 P29466 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTT P42858 1/20 0.37
JAK2 O60674 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2199850 0.94 MAPK13 (0.52) MAPK13MAPK12MAPK11MAPK14CYP3A4
SCHEMBL2855620 0.86 MAPT (0.45) MAPK13MAPK12MAPK11MAPK14ALDH1A1
SCHEMBL2857986 0.86 ALDH1A1 (0.45) MAPK13MAPK12MAPK11MAPK14ALDH1A1
SCHEMBL5174489 0.82 CYP3A4 (0.50) MAPK13MAPK12MAPK11MAPK14CYP3A4
SCHEMBL7035012 0.78 CYP3A4 (0.48) MAPK13MAPK12MAPK11MAPK14CYP3A4
SCHEMBL2198191 0.78 SRD5A2 (0.47) MAPK13MAPK12MAPK11MAPK14CYP3A4
SCHEMBL2196860 0.78 MAPK13 (0.46) MAPK13MAPK12MAPK11MAPK14CYP3A4
SCHEMBL2200547 0.78 KMT2A (0.50) MAPK13MAPK12MAPK11MAPK14ALDH1A1
SCHEMBL5172393 0.77 MAPK13 (0.61) MAPK13MAPK12MAPK11MAPK14CYP3A4
SCHEMBL7090488 0.77 JAK2 (0.53) CYP3A4ALDH1A1KDM4EMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101115728-B Triazole substituted aminobenzophenone compounds LEO PHARMA AS 2012-12-19 CN disclosed
US-8293772-B2 Triazole substituted aminobenzophenone compounds LEO PHARMA A/S (DK) 2012-10-23 US disclosed
EP-1828148-B1 TRIAZOLE SUBSTITUTED AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2010-01-20 EP disclosed
CN-101115728-A Triazole substituted aminobenzophenone compounds LEO PHARMA AS (DK) 2008-01-30 CN disclosed
US-20060128766-A1 Triazole substituted aminobenzophenone compounds LEO PHARMA A/S (DK) 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128766-A1 Triazole substituted aminobenzophenone compounds NFKBIA, UACA, CYP1B1 MAPK13 1436/4885MAPK12 1829/4885MAPK11 919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.